EMEA-002168-PIP01-17-M04 - paediatric investigation plan
Onasemnogene abeparvovec
PIPHuman
Novartis Gene Therapy EU Limited
paediatric.enquiries@novartis.com
+41 613241111
P/0015/2022: EMA decision of 31 January 2022 on the acceptance of a modification of an agreed paediatric investigation plan for onasemnogene abeparvovec (Zolgensma), (EMEA-002168-PIP01-17-M04)